Other Viruses Citation List: August 30 - September 12, 2013
Hepatitis B Virus
1. Therapeutic Potential of Furin Inhibitors for the Chronic Infection of Hepatitis B Virus. Pang, Y.J., X.J. Tan, D.M. Li, Z.H. Zheng, R.X. Lei, and X.M. Peng. Liver International, 2013. 33(8): p. 1230-1238; PMID[23617302].
[PubMed] OV_0830-091213.
Hepatitis C Virus
2. Peroxisome Proliferator-activated Receptor Delta Antagonists Inhibit Hepatitis C Virus RNA Replication. Ban, S., Y. Ueda, M. Ohashi, K. Matsuno, M. Ikeda, N. Kato, and H. Miyachi. Bioorganic & Medicinal Chemistry Letters, 2013. 23(17): p. 4774-4778; PMID[23891183].
[PubMed] OV_0830-091213.
3. Synthesis and Broad Spectrum Antiviral Evaluation of bis(POM) Prodrugs of Novel Acyclic Nucleosides. Hamada, M., V. Roy, T.R. McBrayer, T. Whitaker, C. Urbina-Blanco, S.P. Nolan, J. Balzarini, R. Snoeck, G. Andrei, R.F. Schinazi, and L.A. Agrofoglio. European Journal of Medicinal Chemistry, 2013. 67: p. 398-408; PMID[23911854].
[PubMed] OV_0830-091213.
4. The Antiviral Activity of Poly-gamma-Glutamic acid, a Polypeptide Secreted by Bacillus sp., through Induction of CD14-Dependent Type I Interferon Responses. Lee, W., S.H. Lee, D.G. Ahn, H. Cho, M.H. Sung, S.H. Han, and J.W. Oh. Biomaterials, 2013. [Epub ahead of print]; PMID[24016850].
[PubMed] OV_0830-091213.
5. Suppressive Effect of the Histone Deacetylase Inhibitor Suberoylanilide hydroxamic acid (SAHA) on Hepatitis C Virus Replication. Sato, A., Y. Saito, K. Sugiyama, N. Sakasegawa, T. Muramatsu, S. Fukuda, M. Yoneya, M. Kimura, H. Ebinuma, T. Hibi, M. Ikeda, N. Kato, and H. Saito. Journal of Cellular Biochemistry, 2013. 114(9): p. 1987-1996; PMID[23519646].
[PubMed] OV_0830-091213.
6. Protein Phosphatase 2A Impairs IFNalpha-induced Antiviral Activity against the Hepatitis C Virus through the Inhibition of STAT1 Tyrosine Phosphorylation. Shanker, V., G. Trincucci, H.M. Heim, and H.T. Duong. Journal of Viral Hepatitis, 2013. 20(9): p. 612-621; PMID[23910645].
[PubMed] OV_0830-091213.
7. Synthesis and Biological Activity of Benzo-fused 7-Deazaadenosine Analogues. 5- and 6-Substituted 4-Amino- or 4-alkylpyrimido[4,5-b]indole ribonucleosides. Tichy, M., R. Pohl, E. Tloust'ova, J. Weber, G. Bahador, Y.J. Lee, and M. Hocek. Bioorganic & Medicinal Chemistry, 2013. 21(17): p. 5362-5372; PMID[23827234].
[PubMed] OV_0830-091213.
8. New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication. Ueda, Y., M. Takeda, K. Mori, H. Dansako, T. Wakita, H.S. Kim, A. Sato, Y. Wataya, M. Ikeda, and N. Kato. Plos One, 2013. 8(8): p. e72519; PMID[24023620].
[PubMed] OV_0830-091213.
9. In Vitro Efficacy of Approved and Experimental Antivirals against Novel Genotype 3 Hepatitis C Virus Subgenomic Replicons. Yu, M., A.C. Corsa, S. Xu, B. Peng, R. Gong, Y.J. Lee, K. Chan, H. Mo, W.t. Delaney, and G. Cheng. Antiviral Research, 2013. [Epub ahead of print]; PMID[24013001].
[PubMed] OV_0830-091213.
Human Cytomegalovirus
10. Antibody Inhibition of Human Cytomegalovirus Spread in Epithelial Cell Cultures. Cui, X., R. Lee, S.P. Adler, and M.A. McVoy. Journal of Virological Methods, 2013. 192(1-2): p. 44-50; PMID[23669101].
[PubMed] OV_0830-091213.
11. Stability and Antiviral Activity against Human Cytomegalovirus of Artemisinin Derivatives. Flobinus, A., N. Taudon, M. Desbordes, B. Labrosse, F. Simon, M.C. Mazeron, and N. Schnepf. The Journal of Antimicrobial Chemotherapy, 2013. [Epub ahead of print]; PMID[24003183].
[PubMed] OV_0830-091213.
Citations from the ISI Web of Knowledge Listings for O.V.
12. Fragment Based Drug Discovery of New Cyclophilin Inhibitors Unrelated to Cyclosporine A That Potently Inhibit HCV Replication. Ahmed-Belkacem, A., L. Colliandre, N. Ahnou, P. Barthe, W. Bourget, D. Douguet, J.F. Guichou, and J.M. Pawlotsky. Journal of Hepatology, 2013. 58: p. S481-S481; ISI[000322983001444].
[WOS] OV_0830-091213.
13. GS-5816, a Second Generation HCV NS5A Inhibitor with Potent Antiviral Activity, Broad Genotypic Coverage and a High Resistance Barrier. Cheng, G., M. Yu, B. Peng, Y.J. Lee, A. Trejo-Martin, R. Gong, C. Bush, A. Worth, M. Nash, K. Chan, H. Yang, R. Beran, Y. Tian, J. Perry, J. Taylor, C. Yang, M. Paulson, W. Delaney, and J.O. Link. Journal of Hepatology, 2013. 58: p. S484-S485; ISI[000322983001451].
[WOS] OV_0830-091213.
14. Synthesis and anti-HCV Activity of 2,6-Bisarylmethyloxy-5-hydroxy-7-phenylchromones. Cho, S.Y., C.W. Lee, and Y.H. Chong. Bulletin of the Korean Chemical Society, 2013. 34(7): p. 1953-1954; ISI[000322612400003].
[WOS] OV_0830-091213.
15. Synergistic Interactions of HCV NS5A Replication Complex Inhibitors Sensitize Resistant Variants and Enhance the Efficacy of Daclatasvir (DCV, BMS-790052) in Vitro and in Vivo. Gao, M., D.R. O'Boyle, J.A. Lemm, R.A. Fridell, C. Wang, S. Roberts, M. Liu, P. Nower, Y.K. Wang, B.M. Johnson, M. Kramer, F. Moulin, M.J. Nophsker, P. Hewawasam, J. Kadow, M. Cockett, N.A. Meanwell, M. Belema, and J.H. Sun. Journal of Hepatology, 2013. 58: p. S573-S574; ISI[000322983001682].
[WOS] OV_0830-091213.
16. Cyclophilin Inhibitor Alisporivir (ALV) Combinations with Direct Acting Antivirals Reveal Strong Synergistic anti-HCV Effects. Garcia-Rivera, J., U. Chatterji, and P. Gallay. Journal of Hepatology, 2013. 58: p. S469-S469; ISI[000322983001413].
[WOS] OV_0830-091213.
17. BL-8030: A Novel, Potent, Selective, Orally Available Inhibitor of Hepatitis C Virus NS3/4A Protease. Halfon, P., J. Courcambeck, T. Whitaker, P.M. Tharnish, T.R. McBrayer, S.J. Coats, Y. Pereg, R. Tabakman, J. Schumann, M. Matto, and R.F. Schinazi. Journal of Hepatology, 2013. 58: p. S475-S475; ISI[000322983001428].
[WOS] OV_0830-091213.
18. Interferon alfa Partially Inhibits HIV Replication in Hepatocytes in Vitro. Kong, L. and J.T. Blackard. Journal of Infectious Diseases, 2013. 208(5): p. 865-866; ISI[000322958900021].
[WOS] OV_0830-091213.
19. Turmeric Curcumin Inhibits Entry of All Hepatitis C Virus Genotypes into Human Liver Cells. Kusuma, A., C.C. Colpitts, L.M. Schang, H. Rachmawati, A. Frentzen, S. Pfaender, P. Behrendt, R.J.P. Brown, D. Bankwitz, J. Steinmann, M. Ott, P. Meuleman, T. Pietschmann, and E. Steinmann. Journal of Hepatology, 2013. 58: p. S473-S473; ISI[000322983001422].
[WOS] OV_0830-091213.
20. Preliminary Evaluation of a New Autophagy Inhibitor Antiviral Agent for Hepatitis C Virus in an ex Vivo Model of Human Liver Slices Culture. Lagaye, S., H. Shen, J. Gaston, G. Rousseau, P.P. Massault, A. Vallet-Pichard, P. Sogni, V. Mallet, J. Courcambeck, S. Brun, F. Bassisi, C. Camus, P. Halfon, and S. Pol. Journal of Hepatology, 2013. 58: p. S490-S490; ISI[000322983001465].
[WOS] OV_0830-091213.
21. Unusual nor-Sesquiterpene lactone from the Fruits of Illicium henryi. Liu, J.F., Y.F. Wang, Y.P. Bi, H.J. Li, L. Jia, Y.F. Bi, and Y.B. Zhang. Tetrahedron Letters, 2013. 54(36): p. 4834-4836; ISI[000323093300005].
[WOS] OV_0830-091213.
22. A New Role for the Cellular PABP Repressor PAIP2 as an Innate Restriction Factor Capable of Limiting Productive Cytomegalovirus Replication. McKinney, C., D. Yu, and I. Mohr. Genes & Development, 2013. 27(16): p. 1809-1820; ISI[000323416000007].
[WOS] OV_0830-091213.
23. A 96-Well Based Analysis of Replicon Elimination with the HCV NS5A Replication Complex Inhibitor Daclatasvir. O'Boyle, D.R., P.T. Nower, J.H. Sun, R. Fridell, C.F. Wang, L. Valera, and M. Gao. Journal of Virological Methods, 2013. 193(1): p. 68-76; ISI[000323362100011].
[WOS] OV_0830-091213.
24. Cyclophilin Inhibitor EDP-546 Is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to Its High Barrier to HCV Resistance. Owens, C.M., M.H.J. Rhodin, A. Polemeropoulos, J. Long, G. Wang, L. Jiang, and Y.S. Or. Journal of Hepatology, 2013. 58: p. S493-S493; ISI[000322983001473].
[WOS] OV_0830-091213.
25. A Nanobody Recognizing a Novel Epitope in Hepatitis C Virus Glycoprotein E2 Broadly Neutralizes Virus Entry and Inhibits Cell-Cell Transmission. Tarr, A.W., P. Lafaye, L. Damier-Piolle, L. Meredith, R.A. Urbanowicz, A. Meola, J.L. Jestin, R.J.P. Brown, J.A. McKeating, F.A. Rey, J.K. Ball, and T. Krey. Journal of Hepatology, 2013. 58: p. S479-S479; ISI[000322983001438].
[WOS] OV_0830-091213.
26. Potential Role for Statins in the Treatment of Chronic HCV Infection. Zhu, Q.Q., Q.Y. Han, and Z.W. Liu. Future Virology, 2013. 8(8): p. 727-729; ISI[000323231900001].
[WOS] OV_0830-091213.